EACS recommendations for development of new therapies can be summarized as follows:
Increase support to academia-initiated clinical trials (including diagnostics, drug development, radiation therapy, associated translational research, surgery and multimodal treatment).
Encourage and support research in drug repurposing to ﬁnd new applications of well-established and widely available generic medicines.
Adopt existing and create new innovative investigator-initiated trial concepts such as Drug Rediscovery Protocol or basket studies, exploring new engagement paradigms with the pharmaceutical industry.
Support treatment optimization research to identify the optimal dosage and duration of existing treatments, both for the beneﬁt of patients and to guarantee the sustainability of healthcare systems.
Improve stratiﬁcation methods of patients using multi-omics, novel complex multilayer biomarkers based on systems biology models.
Develop methodologies for predicting treatment outcomes (in silico studies).
Stimulate development and application of new functional and molecular imaging technologies (including radiomics).
Increase support to already-established multicentre platforms for early drug development.
Develop new sophisticated in vitro and in vivo functional screening methods (e.g. Interspaced clustered regularly short palindromic repeats/Cas9 based in preclinical models, i.e. Patient-derived xenografts or organoids) to identify new therapeutic paradigms.
Support the development of academic cell therapy entities (e.g. Chimeric antigen receptor T cells cell production) to boost further innovation in less toxic immunotherapy approaches.
Promote integration of advanced computational methods (AI, machine learning) with clinical research.
Structure implementation research in therapeutics to effectively introduce practice-changing therapies.